Colgate Palmolive logo

Colgate Palmolive

COLPAL NSE

Key Fundamentals

MidcapPersonal CareConsumer Goods
Market Cap
₹48,601 Cr
Volatility
Moderate
P/E Ratio
36.27
EBITDA
₹1,959 Cr
Return on Equity
83.66%
Debt to Equity
0.03
Book Value
₹58.24
EPS
₹51.99
52W High
₹2,417.6
52W Low
₹1,782

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

4
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 79.4%
  • Company has been maintaining a healthy dividend payout of 112%

Weaknesses

2
  • Stock is trading at 30.9 times its book value
  • The company has delivered a poor sales growth of 4.51% over past five years.

Growth Rate

Revenue Growth
-0.89% lower than 3Y
Net Income Growth
-7.76% lower than 3Y
Cash Flow Change
29.53% lower than 3Y
ROE
-3.08% lower than 3Y
ROCE
-3.34% lower than 3Y
EBITDA Margin (Avg.)
-5.77% higher than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2d ago
AI opinion · based on fundamentals
Risk medium

Colgate-Palmolive (India) Ltd commands a market cap of ₹48,601 Cr with a PE of 36.5x and an exceptionally high ROE of 83% (last year). However, the company faces sluggish top-line growth at a 5-year sales CAGR of just 5% and the stock has declined 24% over the past year, reflecting a disconnect between premium valuation and muted growth.

Bull Case 7
  • Exceptional return on equity with last year ROE at 83% and a 3-year average ROE of 79%, indicating highly efficient capital deployment relative to shareholder equity
  • Virtually debt-free balance sheet, reducing financial risk and interest burden, which supports margin stability through economic cycles
  • Consistent dividend payout of 112% of profits, translating to a dividend yield of 2.65% — attractive for a consumer staples name and well above sector median
  • Compounded profit growth of 8% over 10 years demonstrates long-term earnings resilience and the ability to sustain profitability through multiple market cycles
  • Dominant market position in the oral care category in India backed by the global Colgate-Palmolive parentage, providing brand equity, R&D access, and distribution advantages
  • Steady 3-year compounded sales growth of 5% and profit growth of 8% shows the company can expand earnings faster than revenue, reflecting operating leverage and cost discipline
  • Price-to-book of 31x, while optically high, is partly justified by the asset-light business model that generates 75%+ ROE consistently over 5 years without requiring heavy capital reinvestment
Bear Case 8
  • Stock has declined 24% over the past 1 year, significantly underperforming broader market indices and eroding shareholder value
  • 5-year compounded sales growth of just 5% signals structural top-line stagnation in a market where peers in FMCG are growing faster through premiumisation and new categories
  • Trading at 31x book value — one of the highest PB multiples in the consumer goods space — leaves minimal margin of safety for investors at current levels
  • TTM profit growth has turned negative at -2%, indicating recent earnings pressure possibly from higher input costs or competitive intensity
  • PE ratio of 36.5x is elevated for a company delivering only 4% TTM sales growth, suggesting the valuation assumes a growth re-acceleration that has not yet materialised
  • 10-year stock CAGR of only 6% implies that long-term capital appreciation has barely kept pace with nominal GDP growth, underperforming broader equity benchmarks
  • 3-year stock CAGR of -3% shows that even medium-term holders have experienced negative returns despite the company remaining profitable
  • Dividend payout exceeding 100% of profits at 112% raises sustainability questions — the company is paying out more than it earns, potentially limiting reinvestment capacity for future growth

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 2h ago
Positives 2
  • PerioGard wins ISP seal Aug 18

    Colgate PerioGard became India's first gum care regimen to earn the Indian Society of Periodontology Seal of Acceptance, strengthening clinical credibility in the oral care segment.

  • KBC 18 oral health campaign Sep 10

    Colgate partnered with KBC Season 18 launching Sep 10, 2026, featuring Amitabh Bachchan to promote nighttime brushing, targeting the 9 out of 10 Indians affected by oral health issues.

Neutral 2
  • New MD & CEO appointed Aug 21

    Board approved Manish Anandani as MD & CEO effective Sep 28, 2026, succeeding Prabha Narasimhan who departs for a global role at Colgate-Palmolive.

  • Internal auditor resigns Aug 31

    Mr. G. Ramprasad resigned as Internal Auditor effective Aug 31, 2026, citing a desire to explore external opportunities.

TL;DR: Colgate-Palmolive India shows steady brand-building momentum with a high-visibility KBC 18 campaign and a clinical endorsement for PerioGard. The MD & CEO transition is orderly with a named successor already in place. No material headwinds are visible in recent news. The near-term outlook hinges on smooth leadership handover by late September and sustained consumer demand in oral care.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1,324
1,471
1,396
1,490
1,497
1,619
1,462
1,463
1,434
1,520
1,486
1,595
1,603
Expenses
906
989
927
958
988
1,122
1,007
964
981
1,054
1,044
1,086
1,120
Operating Profit
418
482
468
532
508
497
454
498
453
465
442
510
483
OPM %
32%
33%
34%
36%
34%
31%
31%
34%
32%
31%
30%
32%
30%
Other Income
-5
21
18
23
23
76
20
19
18
15
31
0
19
Interest
1
1
2
1
1
1
1
1
1
1
1
1
1
Depreciation
44
44
41
42
42
42
41
38
38
37
36
35
39
PBT
369
458
443
511
489
530
433
478
432
442
436
474
462
Tax %
26%
26%
26%
26%
26%
26%
25%
26%
26%
26%
26%
25%
26%
Net Profit
274
340
330
380
364
395
323
355
321
328
324
353
343
EPS in Rs
10.06
12.5
12.14
13.96
13.38
14.52
11.87
13.05
11.79
12.04
11.91
12.99
12.61
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
3,982
3,868
3,982
4,188
4,462
4,525
4,841
5,100
5,226
5,680
6,040
6,035
6,204
Expenses
3,159
2,929
3,038
3,074
3,226
3,323
3,331
3,534
3,679
3,779
4,082
4,165
4,304
Operating Profit
823
940
944
1,114
1,236
1,202
1,510
1,566
1,547
1,901
1,958
1,870
1,900
OPM %
21%
24%
24%
27%
28%
27%
31%
31%
30%
33%
32%
31%
31%
Other Income
32
7
41
26
68
49
30
26
42
57
139
64
66
Interest
0
0
0
0
2
10
7
6
5
5
4
4
4
Depreciation
75
111
133
157
159
198
182
177
175
172
163
146
148
PBT
780
835
851
983
1,143
1,043
1,350
1,409
1,410
1,781
1,930
1,784
1,814
Tax %
28%
30%
32%
32%
32%
22%
23%
23%
26%
26%
26%
26%
—
Net Profit
559
581
577
673
776
816
1,035
1,078
1,047
1,324
1,437
1,325
1,348
EPS in Rs
20.55
21.37
21.23
24.76
28.52
30.02
38.07
39.65
38.5
48.67
52.83
48.73
49.55
Div. Payout %
58%
47%
47%
97%
81%
93%
100%
101%
101%
119%
97%
119%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
14
27
27
27
27
27
27
27
27
27
27
27
Reserves
757
1,004
1,247
1,497
1,420
1,567
1,139
1,707
1,689
1,847
1,637
1,557
Borrowings
0
0
0
0
83
102
91
83
69
72
61
47
Other Liabilities
932
972
1,037
1,039
1,097
908
1,637
1,084
1,098
1,250
1,293
1,777
Total Liabilities
1,702
2,003
2,311
2,564
2,626
2,604
2,894
2,902
2,883
3,197
3,019
3,408
Fixed Assets
782
1,008
1,108
1,146
1,191
1,123
1,065
963
862
794
776
718
CWIP
141
78
167
159
199
190
145
122
114
110
38
27
Investments
37
31
31
31
31
19
19
0
0
0
0
0
Other Assets
742
885
1,005
1,228
1,206
1,272
1,666
1,817
1,907
2,292
2,204
2,663
Total Assets
1,702
2,003
2,311
2,564
2,626
2,604
2,894
2,902
2,883
3,197
3,019
3,408
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
638
689
688
694
983
930
784
1,626
1,176
1,199
1,394
1,806
Investing
-272
-237
-342
-207
-96
-19
71
-108
-8
79
56
374
Financing
-385
-391
-341
-380
-815
-891
-956
-1,091
-1,087
-1,195
-1,671
-1,422
Net Cash Flow
-18
61
5
107
73
20
-101
427
82
83
-221
758
Free Cash Flow
339
417
367
485
879
869
727
1,576
1,107
1,123
1,323
1,730
CFO/OP
103
100
105
93
113
104
76
127
101
88
100
121
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
6
10
12
18
17
11
9
16
11
11
14
13
Inventory Days
63
72
72
56
58
69
79
78
68
63
76
75
Days Payable
128
136
148
152
144
142
179
169
155
187
185
275
Cash Conversion Cycle
-59
-55
-63
-79
-68
-63
-91
-75
-76
-113
-95
-188
Working Capital Days
-40
-43
-39
-33
-36
-23
-84
-25
-32
-46
-37
-59
ROCE %
114%
96%
74%
71%
73%
65%
92%
92%
79%
97%
105%
108%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Colgate Palmolive insights

70 extracted metrics + investor summaries across FY02–FY26.

Log in — free

Shareholding Pattern

Others2.57%Govt.0.28%Promot.51.00%FIIs13.59%DIIs15.54%Public17.01%As ofJun 2026

Documents

Frequently Asked Questions about Colgate Palmolive

What does Colgate-Palmolive (India) Ltd do?
Colgate-Palmolive India Ltd is engaged in manufacturing/ trading of toothpaste, tooth powder, toothbrush, mouthwash and personal care products.[1]
Where is Colgate-Palmolive (India) Ltd (COLPAL) listed?
Colgate-Palmolive (India) Ltd trades as COLPAL on the NSE and under code 500830 on the BSE.
Which sector does Colgate-Palmolive (India) Ltd belong to?
Colgate-Palmolive (India) Ltd is classified under the Consumer Goods sector, in the Personal Care industry.
What is the market capitalisation of Colgate-Palmolive (India) Ltd?
Colgate-Palmolive (India) Ltd has a market capitalisation of ₹48,601 Cr, which places it in the Large Cap band.
What is the PE ratio of Colgate-Palmolive (India) Ltd?
Colgate-Palmolive (India) Ltd trades at a PE ratio of 36.27, on earnings per share of ₹51.99, against a book value of ₹58.24 per share.
What is the 52-week high and low of Colgate-Palmolive (India) Ltd?
Over the last 52 weeks Colgate-Palmolive (India) Ltd has traded between ₹1,782 and ₹2,417.6.
Does Colgate-Palmolive (India) Ltd pay dividends?
Colgate-Palmolive (India) Ltd has a dividend yield of 2.65%.
What is the Return on Equity (ROE) of Colgate-Palmolive (India) Ltd?
Colgate-Palmolive (India) Ltd reported a return on equity of 83.66%. Its debt-to-equity ratio is 0.03.

Company Information

Colgate-Palmolive India Ltd is engaged in manufacturing/ trading of toothpaste, tooth powder, toothbrush, mouthwash and personal care products.[1]

Website colgate.co.in
CEO Ms. Prabha Narasimhan
Employees 2,198
Listed 2007-12-17
Face Value ₹ 1
Issued Size 27,19,85,634

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/COLPAL.md for Colgate-Palmolive (India) Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Consumer Goods → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List